Why the McPherson's (ASX:MCP) share price could charge higher on Tuesday

The McPherson's Ltd (ASX:MCP) share price will be one to watch on Tuesday following an after market update today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The McPherson's Ltd (ASX: MCP) share price will be on watch on Tuesday following the release of a trading update after the market close.

What did McPherson's announce?

This afternoon McPherson's confirmed that sales from its core brands in the Australian market continue to exceed last year's figures.

According to the release, year to date, the company's owned brands, excluding the Dr. LeWinn's brand, have recorded sales growth of 7%.

This has been driven by double digit sales growth from the Manicare, Lady Jayne, and A'kin brands. Furthermore, market share growth has been recorded from 4 out of 6 of its owned brands.

The Dr. LeWinn's brand continues to weigh on the company's performance, though. Like A2 Milk Company Ltd (ASX: A2M), this has been caused by weakness in the daigou channel.

However, unlike a2 Milk, the sales of these products inside China haven't been strong, with Chinese Singles' Day sales falling well short of expectations.

Global Therapeutics acquisition.

In addition to this, the company revealed that the Global Therapeutics acquisition from Blackmores Limited (ASX: BKL) completed successfully on 30 November and its integration is progressing smoothly.

Management believes that this reflects the professional, collaborative approach of Global Therapeutics, McPherson's, and Blackmores.

McPherson's new Chief Executive Officer and Managing Director, Grant Peck, commented: "McPherson's year to date domestic sales growth reflects the consumer appeal of our market leading brands and our focus on new product innovation. All of the early signs are positive as we integrate Global Therapeutics into McPherson's and realise the complementary capabilities of the combined teams. Domestically, we continue to drive cashflow to support our mature dividend profile and modest debt levels."

Mr Peck, who was appointed CEO earlier this month after the sudden departure of Laurie McAllister following a series of terrible updates, also provided the market with guidance for the first half of FY 2021.

He revealed that McPherson's is on track to achieve its previous first half underlying profit before tax guidance in the range of $6.5 million to $7.5 million. This represents an 11.8% to 23.5% decline on the prior corresponding period's profit before tax of $8.5 million.

In addition to this, the new chief executive revealed that shareholders should expect a dividend March. He advised that the company's dividend policy is to pay a minimum dividend of 60% of underlying profit after tax, subject to cash requirements.

In line with this policy and based on its forecast first half underlying earnings, an interim fully franked dividend of at least 3 cents per share is expected to be paid to shareholders in March.

Annualised, this represents a fully franked 4.5% dividend yield. This may be far better than many had expected after its recent updates and guidance withdrawal.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended A2 Milk and Blackmores Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

A group of three men in hard hats and high visibility vests stand together at a mine site while one points and the others look on with piles of dirt and mining equipment in the background.
Broker Notes

How high does Macquarie think Fortescue shares will go?

The broker is positive on the company's outlook.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Broker Notes

Experts name 3 big-name ASX 200 shares to sell

These shares are in the bad books, but for what reason?

Read more »

Two smiling work colleagues discuss an investment at their office.
Broker Notes

Why Mesoblast shares could double in value

This biotechnology company just became less risky according to Bell Potter.

Read more »

Miner looking at a tablet.
Broker Notes

Should you buy BHP shares FY27? Here's what experts are saying

Is another powerful rally on the cards for the mining giant?

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Buy, hold, sell: TechnologyOne, Pro Medicus, PLS Group shares

Here's what John Athanasiou from Red Leaf Securities thinks of these three ASX 200 shares.

Read more »

A trio of ASX shares analysts huddle together in an office with computer screens all around them showing share price movements
Broker Notes

Buy, hold, sell: James Hardie, Adairs, Minerals 260 shares

Morgans has updated its ratings on these three ASX shares.

Read more »

The words short selling in red against a black background
ASX Share Market News

These are the 10 most shorted ASX shares

Short sellers have their eyes on these shares.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
ASX Share Market News

5 things to watch on the ASX 200 on Monday

It looks set to be a good start to the week for Australian investors.

Read more »